Page 257 - Binder2
P. 257
Trust doesn’t come from the molecule.
It comes from how you tell the story—and who tells it with
you.
The Path Forward
The promise of edible biologics is no longer theoretical.
The proof is emerging—in preclinical models, pilot trials,
and early-stage manufacturing platforms around the world.
The proteins work.
The plants grow.
The immune system responds.
But innovation alone isn’t enough.
To make edible biologics real—not just in the lab, but in
the lives of patients—we need to build the systems that
can support them.
That requires more than enthusiasm. It requires
intentionality.
Because while the roadblocks—scientific, regulatory,
operational—are real, they are not insurmountable. What
they demand is a coordinated, deliberate effort across
disciplines and sectors. Not just a pipeline of new products,
but a blueprint for a new class of medicine.
To move from pilot programs to global adoption, the edible
biologics movement must do five things—and do them
well:
255
